ArticleMolecular informatics2025
Update and ADMET Profile of the Latin American Natural Product Database: LANaPDB.
Article in Molecular informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Computational applications in secondary metabolite discovery (CAiSMD) 2026: focus on secondary metabolites towards drug discovery.Journal of cheminformatics · 2026Article
- Update and ADMET Profile of the Latin American Natural Product Database: LANaPDB.Molecular informatics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For more than 5 years, several countries in Latin America have been developing and updating compound databases of natural products (NPs) isolated and characterized by their countries. In parallel, multiple research groups have been collaborating and assembling a unified Latin American Natural Product Database (LANaPDB), an open-access compound collection representative of Latin America that stands out as a geographical region distinct from its vastness and richness of NP resources. Herein, we report a significant update of LANaPDB, which gathers NPs from eight countries. Major updates to the database include adding 1,164 new compounds obtained from NaturAr, a NP collection from Argentina published in 2025, and 132 new compounds from Panama. The updated LANaPDB has 14,742 nonduplicate compounds. Moreover, a comprehensive evaluation of 41 ADMET (absorption, distribution, metabolism, excretion, and toxicity)-related parameters was carried out for LANaPDB, and the results were compared with one of the largest NP databases, the Universal Natural Product Database, and the approved small-molecule drugs. The results indicated that the three databases have a very similar ADMET profile. Besides, most of the LANaPDB compounds presented high bioavailability, volume of distribution, plasma protein binding rate, blood-brain barrier penetration, susceptibility to CYP3A4, and half-life less than 12 h. Moreover, most of the LANaPDB compounds were predicted with a low probability of inducing toxicity-related reactions. The third version of LANaPDB and the codes for the curation and determination of 41 ADMET-related parameters are freely available at https://doi.org/10.5281/zenodo.15595030. The code is general and can be used to analyze other compound libraries.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.